BioAdvance News BobcatBio Portfolio News

SIRPant Immunotherapeutics (now BobcatBio) Announces FDA Clearance of IND Application for SIRPant-M™ Autologous SIRPαlow Activated Macrophage Immunotherapy

By WebmasterMay 1, 2023March 18th, 2026No Comments

SIRPant Immunotherapeutics (now BobcatBio) Announces FDA Clearance of IND Application for SIRPant-M™ Autologous SIRPαlow Activated Macrophage Immunotherapy

See more here

Previous PostVESTECK SAB Member Accepts International Leadership Appointment
Next PostTreventis Partners its Preclinical Program in Alzheimer's Disease with Takeda

SIRPant Immunotherapeutics (now BobcatBio) Announces FDA Clearance of IND Application for SIRPant-M™ Autologous SIRPαlow Activated Macrophage Immunotherapy

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostVESTECK SAB Member Accepts International Leadership Appointment

Next PostTreventis Partners its Preclinical Program in Alzheimer's Disease with Takeda